摘要
目的:研究贯叶连翘Hypericum perforatum L.的化学成分及降糖活性。方法:运用硅胶柱色谱、ODS柱色谱、Sephadex LH-20葡聚糖凝胶柱色谱以及制备HPLC等多种方法对贯叶连翘地上部分95%乙醇提取物进行分离纯化,利用HR-ESI-MS、NMR等波谱技术对分离得到的化合物进行鉴定。通过体外α-葡萄糖苷酶活性抑制试验,测定化合物的降糖活性。结果:从贯叶连翘中分离得到14个化合物,分别鉴定为:北美芹素(1)、3′,4′-disenecioyl-cis-khellactone(2)、5,4′-二羟基-6,8-二甲基-7-甲氧基黄酮(3)、5,4′-二羟基-6-甲基-7-甲氧基黄酮(4)、5,7-二羟基-3-甲基色原酮(5)、5,7-二羟基-3-乙基色原酮(6)、2,4,6-三羟基苯甲酸乙酯(7)、香草醛(8)、7-hydroxy-5-methoxy-4,6-dimethylphthalidc(9)、α-生育醌(10)、豆甾醇(11)、乙酰-11-羰基-β-乳香酸(12)、阿魏酸二十六烷酯(13)、cosmosoic acid(14)。结论:其中,化合物1~4、10、12~14为首次从金丝桃属植物中分离得到,化合物5~7、9为首次从贯叶连翘中分离得到。化合物3和4表现出较好的α-葡萄糖苷酶抑制活性,其IC_(50)值分别为490.3和549.9μmol/L,与阳性药阿卡波糖效果(IC_(50)=500.1μmol/L)相当。
Objective:To study the chemical constituents of Hypericum perforatum and hyperglycemic activity.Methods:The 95%ethanol extract of the aerial part of Hypericum perforatum was isolated and purified by silica gel column chromatography,ODS column chromatography,Sephadex LH-20 column chromatography and preparative HPLC,the structures were identified by HR-ESI-MS and NMR spectral techniques.Theα-glucosidase inhibitory assay(in vitro)was used to determine the hypoglycemic activity of the compounds.Results:Fourteen compounds were isolated from Hypericum perforatum and identified as pteryxin(1),3′,4′-disenecioyl-ciskhellactone(2),5,4′-dihydroxy-6,8-di-C-methyl-7-methoxy-flavanone(3),5,4′-dihydroxy-6-C-methyl-7-methoxy-flavanone(4),5,7-dihydroxy-3-methylchromone(5),5,7-dihydroxy-3-ethylchromone(6),ethyl-2,4,6-trihydroxybenzoate(7),vanillin(8),7-hydroxy-5-methoxy-4,6-dimethylphthalidc(9),α-tocopherol quinone(10),stigmasterol(11),acetyl-11-keto-β-boswellic acid(12),ferulic acid hexacosanyl ester(13),cosmosoic acid(14),respectively.Conclusion:Among them,compounds 1 to 4,10,12 to 14 are isolated from Hypericum genus for the first time,compounds 5 to 7,9 are isolated from Hypericum perforatum for the first time.Compounds 3,4 show betterα-glucosidase inhibitory activity with IC_(50) values of 490.3,549.9μmol/L,respectively,which are similar to that of acarbose with IC_(50) value of 500.1μmol/L.
作者
李昕昕
赫军
殷伟峰
王利杰
陈欣
张维库
续洁琨
LI Xin-xin;HE Jun;YIN Wei-feng;WANG Li-jie;CHEN Xin;ZHANG Wei-ku;XU Jie-kun(School of Chinese Materia Medica&School of Life Sciences,Beijing University of Chinese Medicine,Beijing 100029,China;Institute of Clinical Medical Sciences&Department of Pharmacy,China-Japan Friendship Hospital,Beijing 100029,China;School of Chinese Materia Medica,Shenyang Pharmaceutical University,Shenyang 110016,China)
出处
《中药材》
CAS
北大核心
2023年第9期2201-2205,共5页
Journal of Chinese Medicinal Materials
基金
中央高水平医院临床科研业务费(2023-NHLHCRF-CXYW-01,2022-NHLHCRF-YNZJ-01)
中日友好医院菁英计划(ZRJY2021-BJ06,ZRJY2021-TD06)。